Epalrestat (150mg) + Methylcobalamin (1500mcg) + Pregabalin (150mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) therapy primarily indicated for the management of painful diabetic peripheral neuropathy (DPN). Epalrestat is an aldose reductase inhibitor that targets the polyol pathway, a key contributor to diabetic nerve damage. Methylcobalamin is an active form of Vitamin B12 that supports nerve regeneration and myelin synthesis. Pregabalin is a gabapentinoid that modulates calcium channels to provide central analgesic and neuropathic pain relief. This combination offers a multi-modal approach targeting both the underlying pathophysiology and symptomatic pain relief in diabetic neuropathy.

The combination works via complementary mechanisms. Epalrestat inhibits aldose reductase, the first enzyme in the polyol pathway, reducing the accumulation of sorbitol and fructose in nerves, which is implicated in osmotic stress, oxidative damage, and reduced nerve conduction velocity in hyperglycemia. Methylcobalamin acts as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase, essential for myelin synthesis, nucleic acid production, and nerve regeneration. It may also promote nerve repair. Pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters (e.g., glutamate, substance P, noradrenaline), thereby dampening central sensitization and neuropathic pain signaling.